Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP versus Omniplasma coagulation study in pediatric congenital heart surgery
NL-OMON58927Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of octaplas lg and fresh-frozen plasma in Cardiovascular Malformation (CVM) (2 arms), sponsored by Erasmus MC. Primary endpoints: Difference in coagulation variables just after surgery and Main coagulation variables of interest. Started Sep 2024; status: completed.
02
Drugs
octaplas lgfresh-frozen plasma
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on NL-OMON58927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58927.